KPW
FOLD

Kore Private Wealth’s Amicus Therapeutics FOLD Stock Holding History

Kore Private Wealth’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,000
Closed -$15K – 554
2020
Q2 		$15K Hold
1,000
– – ﹤0.01% 707
2020
Q1 		$9K Hold
1,000
– – ﹤0.01% 706
2019
Q4 		$10K Buy
+1,000
New +$9.15K ﹤0.01% 741

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Kore Private Wealth's FOLD Position: Q3 2020 in Review

Kore Private Wealth sold out of Amicus Therapeutics (FOLD) in Q3 2020, closing a stake of 1,000 shares — an estimated $15K sold.

Kore Private Wealth first reported a position in FOLD in Q4 2019 and held it in 3 quarters. The position peaked at $15K in Q2 2020. 251 funds tracked by Wall St. Rank hold FOLD as of Q3 2020.

  • Kore Private Wealth reported no remaining Amicus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 1,000 Amicus Therapeutics shares in Q3 2020, an estimated $15K.
  • Kore Private Wealth first reported a position in Amicus Therapeutics in Q4 2019 and held it in 3 quarters.
  • Kore Private Wealth's Amicus Therapeutics position peaked at $15K in Q2 2020.
  • 251 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.